Webinar Video | Life Sciences Session #4: How to optimise your regulatory exclusivity rights for pharmaceutical products?

Webinar Video | Life Sciences Session #4: How to optimise your regulatory exclusivity rights for pharmaceutical products?
May 25, 2021

In the fourth online Life Sciences Session our experts, Kirian Claeyé and Laura Traest, will be focusing on regulatory exclusivity rights for pharmaceutical products, which will include data exclusivity, orphan exclusivity, SPCs and paediatric rewards. They will navigate the maze of regulatory exclusivity rights, update you on a number of significant recent developments, and discuss what is still to come. Specific topics will include:

  • The SPC manufacturing waiver
  • The CJEU’s latest case-law on SPC rights: Santen and Royalty Pharma
  • The European Commission’s review of Orphan Exclusivity and Paediatric Extensions
  • The General Court’s very recent Polpharma ruling on Data Exclusivity

Contact

  • Kirian Claeyé

    Partner

Recommended articles

May 03, 2024

EU Court of Justice interprets import ban on Chinese animal products: fish oil for feed is not an exempted “fishery product”

On 21 March 2024, the EU Court of Justice (‘CJEU’) handed down its ruling in case C‑7/23, concerning a dispute between a feed company and the Federal Agency for the Safety of the Food Chain. The parties differed in their interpretation of an EU import ban on products of animal origin coming from China. The Council of State sought the CJEU’s guidance.

Read on
April 26, 2024

CJEU balances strict obligations for wholesalers of medicines with proportional penalties

On 21 September 2023, the EU Court of Justice ('CJEU’) handed down its ruling in the Apotheke B. case (C-47/22), and it is a good example of the high threshold set by the EU Court of Justice to uphold the Community Code’s main aim of protecting public health.

Read on
April 04, 2024

Hospital mergers no longer subject to the Belgian Competition Authority’s prior review

The legislator has now had the last word, by providing that, in principle, hospital mergers are no longer subject to the BCA’s prior review and approval.

Read on